A Pilot Study of Osmotic-Release Methylphenidate (OROS-MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD)

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD. The study involved 255 participants, recruited from six sites.

CTN Protocol ID: 
CTN-0029
DSMB ID: 
DSMB-0029
ClinicalTrials.gov ID: 

Principal Investigator(s)

Eugene Somoza, M.D., Ph.D
University of Cincinnati/Cin ARC
3210 Jefferson Avenue, Suite 6
Cincinnati, OH 45220
Somoza@carc.uc.edu

Theresa Winhusen, Ph.D.
Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division 
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
winhust@ucmail.uc.edu